Investors Archives

Philly Tech Week: Startup Sprint: Investor Speed Networking & Pitch Competition

Published on : April 15, 2024April 15, 2024 Published by : Annabel Baldy

Join Cozen O’Connor and PACT during Philly Tech Week for an opportunity to be part of a dynamic speed-dating style networking event that brings together visionaries, investors, and innovators. Whether [….]

How to Network with Investors

Published on : January 18, 2024January 18, 2024 Published by : Chris Frew

How to Network with Investors: JLABS@DC. Networking with investors is a vital part of growing a life science startup company.

BioSpark Virginia

Published on : October 2, 2023October 10, 2023 Published by : BioBuzz Media

BioSpark Virginia is a competitive live pitch event for Virginia life sciences start-ups, co-sponsored and organized by CvilleBioHub and the University of Virginia Licensing and Ventures Group (LVG). After an [….]

5 Questions with Rachel Rath, MBA, MPH, Director, BARDA Alliance for Johnson & Johnson Innovation, JLABS @ Washington, DC

Published on : February 5, 2021February 5, 2021 Published by : Andy Eckert

Rachel is the Director of the BARDA Alliance for Johnson & Johnson Innovation, based at JLABS @ Washington, DC. In this role, she is responsible for managing the BLUE KNIGHT™ collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA). BLUE KNIGHT™ focuses on addressing public-health threats and emerging infectious diseases by supporting companies with emerging science and technology solutions that aim to improve health security and responses.

Rockville’s Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform

Published on : January 11, 2021January 21, 2021 Published by : BioBuzz Media

– Round co-led by Apeiron Investment Group and Catalio Capital Management – Proceeds support advancement of lead product candidate and next-generation platform for personalized yet off-the-shelf cancer immunotherapies BOSTON & [….]